000272342 001__ 272342
000272342 005__ 20251223103528.0
000272342 0247_ $$2doi$$a10.1212/WNL.0000000000209806
000272342 0247_ $$2pmid$$apmid:39303184
000272342 0247_ $$2ISSN$$a0028-3878
000272342 0247_ $$2ISSN$$a1526-632X
000272342 0247_ $$2altmetric$$aaltmetric:168112109
000272342 037__ $$aDZNE-2024-01159
000272342 041__ $$aEnglish
000272342 082__ $$a610
000272342 1001_ $$00009-0003-8877-6451$$aWang, Xiao$$b0
000272342 245__ $$aAssociation of Neurogranin and BACE1 With Clinical Cognitive Decline in Individuals With Subjective Cognitive Decline.
000272342 260__ $$a[Erscheinungsort nicht ermittelbar]$$bOvid$$c2024
000272342 3367_ $$2DRIVER$$aarticle
000272342 3367_ $$2DataCite$$aOutput Types/Journal article
000272342 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1766397306_14397
000272342 3367_ $$2BibTeX$$aARTICLE
000272342 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000272342 3367_ $$00$$2EndNote$$aJournal Article
000272342 520__ $$aCSF biomarkers have immense diagnostic and prognostic potential for Alzheimer disease (AD). However, AD is still diagnosed relatively late in the disease process, sometimes even years after the initial manifestation of cognitive symptoms. Thus, further identification of biomarkers is required to detect related pathology in the preclinical stage and predict cognitive decline. Our study aimed to assess the association of neurogranin and β-site amyloid precursor protein-cleaving enzyme 1 (BACE1) with cognitive decline in individuals with subjective cognitive decline (SCD).We enrolled participants with available neurogranin and BACE1 measurements in CSF from the DELCODE (DZNE-Longitudinal Cognitive Impairment and Dementia, Germany) cohort. The longitudinal change of Preclinical Alzheimer's Cognitive Composite score was assessed as the primary outcome in participants with SCD and controls. The secondary outcome was defined as conversion of SCD to mild cognitive impairment (MCI) during follow-up. Levels of neurogranin, BACE1, and neurogranin/BACE1 ratio across groups were compared by analysis of covariance after adjustment for demographics. The linear mixed-effects model and Cox regression analysis were applied to evaluate their association with cognitive decline and progression of SCD to MCI, respectively.A total of 530 participants (mean age: 70.76 ± 6.01 years, 48.7% female) were analyzed in the study. The rate of cognitive decline was faster in individuals with SCD with higher neurogranin and neurogranin/BACE1 ratio (β = -0.138, SE = 0.065, p = 0.037, and β = -0.293, SE = 0.115, p = 0.013). Higher baseline neurogranin and neurogranin/BACE1 ratio were associated with an increased rate of conversion from SCD to MCI (hazard ratio [HR] 1.35 per SD, 95% CI 1.03-1.77, p = 0.028, and HR 1.53 per SD, 95% CI 1.13-2.07, p = 0.007). In addition, the impact of higher neurogranin levels on accelerating the rate of cognitive decline was more pronounced in the SCD group than in cognitively unimpaired controls (β = -0.077, SE = 0.033, p = 0.020).Our findings suggest that CSF neurogranin and BACE1 begin to change in the preclinical stage of AD and they are associated with clinical progression in individuals with SCD.
000272342 536__ $$0G:(DE-HGF)POF4-353$$a353 - Clinical and Health Care Research (POF4-353)$$cPOF4-353$$fPOF IV$$x0
000272342 588__ $$aDataset connected to CrossRef, PubMed, , Journals: pub.dzne.de
000272342 650_7 $$0EC 3.4.23.-$$2NLM Chemicals$$aAspartic Acid Endopeptidases
000272342 650_7 $$0EC 3.4.-$$2NLM Chemicals$$aAmyloid Precursor Protein Secretases
000272342 650_7 $$0132654-77-4$$2NLM Chemicals$$aNeurogranin
000272342 650_7 $$0EC 3.4.23.46$$2NLM Chemicals$$aBACE1 protein, human
000272342 650_7 $$2NLM Chemicals$$aBiomarkers
000272342 650_2 $$2MeSH$$aHumans
000272342 650_2 $$2MeSH$$aAspartic Acid Endopeptidases: cerebrospinal fluid
000272342 650_2 $$2MeSH$$aAmyloid Precursor Protein Secretases: cerebrospinal fluid
000272342 650_2 $$2MeSH$$aFemale
000272342 650_2 $$2MeSH$$aMale
000272342 650_2 $$2MeSH$$aCognitive Dysfunction: cerebrospinal fluid
000272342 650_2 $$2MeSH$$aAged
000272342 650_2 $$2MeSH$$aNeurogranin: cerebrospinal fluid
000272342 650_2 $$2MeSH$$aDisease Progression
000272342 650_2 $$2MeSH$$aBiomarkers: cerebrospinal fluid
000272342 650_2 $$2MeSH$$aLongitudinal Studies
000272342 650_2 $$2MeSH$$aMiddle Aged
000272342 650_2 $$2MeSH$$aAged, 80 and over
000272342 7001_ $$0P:(DE-2719)2812392$$aFreiesleben, Silka Dawn$$b1$$udzne
000272342 7001_ $$0P:(DE-2719)9002878$$aSchneider, Luisa-Sophie$$b2$$udzne
000272342 7001_ $$0P:(DE-2719)9000703$$aPreis, Lukas$$b3$$udzne
000272342 7001_ $$0P:(DE-2719)2811122$$aPriller, Josef$$b4
000272342 7001_ $$0P:(DE-2719)2812446$$aSpruth, Eike Jakob$$b5
000272342 7001_ $$0P:(DE-2719)2811720$$aAltenstein, Slawek$$b6$$udzne
000272342 7001_ $$0P:(DE-2719)2812035$$aSchneider, Anja$$b7
000272342 7001_ $$0P:(DE-2719)2811326$$aFließbach, Klaus$$b8$$udzne
000272342 7001_ $$0P:(DE-2719)2811317$$aWiltfang, Jens$$b9
000272342 7001_ $$00000-0001-5785-9594$$aHansen, Niels$$b10
000272342 7001_ $$0P:(DE-2719)2000032$$aJessen, Frank$$b11
000272342 7001_ $$00000-0001-5189-134X$$aRostamzadeh, Ayda$$b12
000272342 7001_ $$0P:(DE-2719)2000005$$aDuzel, Emrah$$b13
000272342 7001_ $$0P:(DE-2719)2811614$$aGlanz, Wenzel$$b14
000272342 7001_ $$0P:(DE-2719)9001517$$aIncesoy, Enise I$$b15
000272342 7001_ $$0P:(DE-2719)2811351$$aBürger, Katharina$$b16$$udzne
000272342 7001_ $$0P:(DE-2719)9002557$$aJanowitz, Daniel$$b17$$udzne
000272342 7001_ $$0P:(DE-2719)9000543$$aEwers, Michael$$b18
000272342 7001_ $$0P:(DE-2719)2812234$$aPerneczky, Robert$$b19
000272342 7001_ $$0P:(DE-2719)9001808$$aRauchmann, Boris Stephan$$b20$$udzne
000272342 7001_ $$0P:(DE-2719)2000026$$aTeipel, Stefan J$$b21
000272342 7001_ $$0P:(DE-2719)2810394$$aKilimann, Ingo$$b22
000272342 7001_ $$0P:(DE-2719)2812583$$aGoerss, Doreen$$b23
000272342 7001_ $$0P:(DE-2719)2000055$$aLaske, Christoph$$b24
000272342 7001_ $$0P:(DE-2719)9001516$$aMunk, Matthias H J$$b25
000272342 7001_ $$0P:(DE-2719)2811324$$aSpottke, Annika$$b26$$udzne
000272342 7001_ $$0P:(DE-2719)2812341$$aRoy, Nina$$b27$$udzne
000272342 7001_ $$0P:(DE-2719)2000008$$aHeneka, Michael$$b28$$udzne
000272342 7001_ $$0P:(DE-2719)2810593$$aBrosseron, Frederic$$b29
000272342 7001_ $$0P:(DE-2719)2000057$$aWagner, Michael$$b30
000272342 7001_ $$0P:(DE-2719)2810544$$aWolfsgruber, Steffen$$b31$$udzne
000272342 7001_ $$0P:(DE-2719)2812825$$aRamirez, Alfredo$$b32
000272342 7001_ $$0P:(DE-2719)2812139$$aKleineidam, Luca$$b33$$udzne
000272342 7001_ $$0P:(DE-2719)9001773$$aStark, Melina$$b34$$udzne
000272342 7001_ $$0P:(DE-2719)2811024$$aPeters, Oliver$$b35
000272342 773__ $$0PERI:(DE-600)1491874-2$$a10.1212/WNL.0000000000209806$$gVol. 103, no. 8, p. e209806$$n8$$pe209806$$tNeurology$$v103$$x0028-3878$$y2024
000272342 8564_ $$uhttps://pub.dzne.de/record/272342/files/DZNE-2024-01159.pdf$$yOpenAccess
000272342 8564_ $$uhttps://pub.dzne.de/record/272342/files/DZNE-2024-01159.pdf?subformat=pdfa$$xpdfa$$yOpenAccess
000272342 909CO $$ooai:pub.dzne.de:272342$$popenaire$$popen_access$$pVDB$$pdriver$$pdnbdelivery
000272342 9101_ $$0I:(DE-588)1065079516$$6P:(DE-2719)2812392$$aDeutsches Zentrum für Neurodegenerative Erkrankungen$$b1$$kDZNE
000272342 9101_ $$0I:(DE-HGF)0$$6P:(DE-2719)9002878$$aExternal Institute$$b2$$kExtern
000272342 9101_ $$0I:(DE-HGF)0$$6P:(DE-2719)9000703$$aExternal Institute$$b3$$kExtern
000272342 9101_ $$0I:(DE-588)1065079516$$6P:(DE-2719)2811122$$aDeutsches Zentrum für Neurodegenerative Erkrankungen$$b4$$kDZNE
000272342 9101_ $$0I:(DE-588)1065079516$$6P:(DE-2719)2812446$$aDeutsches Zentrum für Neurodegenerative Erkrankungen$$b5$$kDZNE
000272342 9101_ $$0I:(DE-588)1065079516$$6P:(DE-2719)2811720$$aDeutsches Zentrum für Neurodegenerative Erkrankungen$$b6$$kDZNE
000272342 9101_ $$0I:(DE-588)1065079516$$6P:(DE-2719)2812035$$aDeutsches Zentrum für Neurodegenerative Erkrankungen$$b7$$kDZNE
000272342 9101_ $$0I:(DE-588)1065079516$$6P:(DE-2719)2811326$$aDeutsches Zentrum für Neurodegenerative Erkrankungen$$b8$$kDZNE
000272342 9101_ $$0I:(DE-588)1065079516$$6P:(DE-2719)2811317$$aDeutsches Zentrum für Neurodegenerative Erkrankungen$$b9$$kDZNE
000272342 9101_ $$0I:(DE-588)1065079516$$6P:(DE-2719)2000032$$aDeutsches Zentrum für Neurodegenerative Erkrankungen$$b11$$kDZNE
000272342 9101_ $$0I:(DE-588)1065079516$$6P:(DE-2719)2000005$$aDeutsches Zentrum für Neurodegenerative Erkrankungen$$b13$$kDZNE
000272342 9101_ $$0I:(DE-588)1065079516$$6P:(DE-2719)2811614$$aDeutsches Zentrum für Neurodegenerative Erkrankungen$$b14$$kDZNE
000272342 9101_ $$0I:(DE-588)1065079516$$6P:(DE-2719)9001517$$aDeutsches Zentrum für Neurodegenerative Erkrankungen$$b15$$kDZNE
000272342 9101_ $$0I:(DE-588)1065079516$$6P:(DE-2719)2811351$$aDeutsches Zentrum für Neurodegenerative Erkrankungen$$b16$$kDZNE
000272342 9101_ $$0I:(DE-HGF)0$$6P:(DE-2719)9002557$$aExternal Institute$$b17$$kExtern
000272342 9101_ $$0I:(DE-588)1065079516$$6P:(DE-2719)9000543$$aDeutsches Zentrum für Neurodegenerative Erkrankungen$$b18$$kDZNE
000272342 9101_ $$0I:(DE-588)1065079516$$6P:(DE-2719)2812234$$aDeutsches Zentrum für Neurodegenerative Erkrankungen$$b19$$kDZNE
000272342 9101_ $$0I:(DE-HGF)0$$6P:(DE-2719)9001808$$aExternal Institute$$b20$$kExtern
000272342 9101_ $$0I:(DE-588)1065079516$$6P:(DE-2719)2000026$$aDeutsches Zentrum für Neurodegenerative Erkrankungen$$b21$$kDZNE
000272342 9101_ $$0I:(DE-588)1065079516$$6P:(DE-2719)2810394$$aDeutsches Zentrum für Neurodegenerative Erkrankungen$$b22$$kDZNE
000272342 9101_ $$0I:(DE-588)1065079516$$6P:(DE-2719)2812583$$aDeutsches Zentrum für Neurodegenerative Erkrankungen$$b23$$kDZNE
000272342 9101_ $$0I:(DE-588)1065079516$$6P:(DE-2719)2000055$$aDeutsches Zentrum für Neurodegenerative Erkrankungen$$b24$$kDZNE
000272342 9101_ $$0I:(DE-588)1065079516$$6P:(DE-2719)9001516$$aDeutsches Zentrum für Neurodegenerative Erkrankungen$$b25$$kDZNE
000272342 9101_ $$0I:(DE-588)1065079516$$6P:(DE-2719)2811324$$aDeutsches Zentrum für Neurodegenerative Erkrankungen$$b26$$kDZNE
000272342 9101_ $$0I:(DE-588)1065079516$$6P:(DE-2719)2812341$$aDeutsches Zentrum für Neurodegenerative Erkrankungen$$b27$$kDZNE
000272342 9101_ $$0I:(DE-HGF)0$$6P:(DE-2719)2000008$$aExternal Institute$$b28$$kExtern
000272342 9101_ $$0I:(DE-588)1065079516$$6P:(DE-2719)2810593$$aDeutsches Zentrum für Neurodegenerative Erkrankungen$$b29$$kDZNE
000272342 9101_ $$0I:(DE-588)1065079516$$6P:(DE-2719)2000057$$aDeutsches Zentrum für Neurodegenerative Erkrankungen$$b30$$kDZNE
000272342 9101_ $$0I:(DE-588)1065079516$$6P:(DE-2719)2810544$$aDeutsches Zentrum für Neurodegenerative Erkrankungen$$b31$$kDZNE
000272342 9101_ $$0I:(DE-588)1065079516$$6P:(DE-2719)2812825$$aDeutsches Zentrum für Neurodegenerative Erkrankungen$$b32$$kDZNE
000272342 9101_ $$0I:(DE-588)1065079516$$6P:(DE-2719)2812139$$aDeutsches Zentrum für Neurodegenerative Erkrankungen$$b33$$kDZNE
000272342 9101_ $$0I:(DE-588)1065079516$$6P:(DE-2719)9001773$$aDeutsches Zentrum für Neurodegenerative Erkrankungen$$b34$$kDZNE
000272342 9101_ $$0I:(DE-588)1065079516$$6P:(DE-2719)2811024$$aDeutsches Zentrum für Neurodegenerative Erkrankungen$$b35$$kDZNE
000272342 9131_ $$0G:(DE-HGF)POF4-353$$1G:(DE-HGF)POF4-350$$2G:(DE-HGF)POF4-300$$3G:(DE-HGF)POF4$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lNeurodegenerative Diseases$$vClinical and Health Care Research$$x0
000272342 9141_ $$y2024
000272342 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS$$d2023-10-21
000272342 915__ $$0StatID:(DE-HGF)0160$$2StatID$$aDBCoverage$$bEssential Science Indicators$$d2023-10-21
000272342 915__ $$0StatID:(DE-HGF)1050$$2StatID$$aDBCoverage$$bBIOSIS Previews$$d2023-10-21
000272342 915__ $$0StatID:(DE-HGF)1190$$2StatID$$aDBCoverage$$bBiological Abstracts$$d2023-10-21
000272342 915__ $$0LIC:(DE-HGF)CCBYNCND4$$2HGFVOC$$aCreative Commons Attribution-NonCommercial-NoDerivs CC BY-NC-ND 4.0
000272342 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR$$bNEUROLOGY : 2022$$d2023-10-21
000272342 915__ $$0StatID:(DE-HGF)9905$$2StatID$$aIF >= 5$$bNEUROLOGY : 2022$$d2023-10-21
000272342 915__ $$0StatID:(DE-HGF)0113$$2StatID$$aWoS$$bScience Citation Index Expanded$$d2023-10-21
000272342 915__ $$0StatID:(DE-HGF)1030$$2StatID$$aDBCoverage$$bCurrent Contents - Life Sciences$$d2023-10-21
000272342 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection$$d2023-10-21
000272342 915__ $$0StatID:(DE-HGF)1110$$2StatID$$aDBCoverage$$bCurrent Contents - Clinical Medicine$$d2023-10-21
000272342 915__ $$0StatID:(DE-HGF)0510$$2StatID$$aOpenAccess
000272342 915__ $$0StatID:(DE-HGF)0410$$2StatID$$aAllianz-Lizenz$$d2023-10-21$$wger
000272342 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline$$d2023-10-21
000272342 915__ $$0StatID:(DE-HGF)0320$$2StatID$$aDBCoverage$$bPubMed Central$$d2023-10-21
000272342 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bClarivate Analytics Master Journal List$$d2023-10-21
000272342 9201_ $$0I:(DE-2719)5000000$$kAG Peters$$lBiomarker-Assisted Early Detection of Dementias$$x0
000272342 9201_ $$0I:(DE-2719)5000007$$kAG Priller$$lTranslational Neuropsychiatry$$x1
000272342 9201_ $$0I:(DE-2719)1811005$$kAG Endres$$lInterdisciplinary Dementia Research$$x2
000272342 9201_ $$0I:(DE-2719)1011305$$kAG Schneider$$lTranslational Dementia Research (Bonn)$$x3
000272342 9201_ $$0I:(DE-2719)1011101$$kPatient Studies (Bonn)$$lPatient Studies (Bonn)$$x4
000272342 9201_ $$0I:(DE-2719)1410006$$kAG Wiltfang$$lMolecular biomarkers for predictive diagnostics of neurodegenerative diseases$$x5
000272342 9201_ $$0I:(DE-2719)1011102$$kAG Jessen$$lClinical Alzheimer’s Disease Research$$x6
000272342 9201_ $$0I:(DE-2719)5000006$$kAG Düzel$$lClinical Neurophysiology and Memory$$x7
000272342 9201_ $$0I:(DE-2719)1111015$$kClinical Research (Munich)$$lClinical Research (Munich)$$x8
000272342 9201_ $$0I:(DE-2719)5000022$$kAG Dichgans$$lVascular Cognitive Impairment & Post-Stroke Dementia$$x9
000272342 9201_ $$0I:(DE-2719)1510100$$kAG Teipel$$lClinical Dementia Research (Rostock /Greifswald)$$x10
000272342 9201_ $$0I:(DE-2719)1210000$$kAG Gasser$$lParkinson Genetics$$x11
000272342 9201_ $$0I:(DE-2719)1011103$$kAG Spottke$$lClinical Research Platform (CRP)$$x12
000272342 9201_ $$0I:(DE-2719)1011401$$kClinical Research Platform (CRP)$$lClinical Research Platform (CRP)$$x13
000272342 9201_ $$0I:(DE-2719)1011303$$kAG Heneka$$lNeuroinflammation, Biomarker$$x14
000272342 9201_ $$0I:(DE-2719)1011201$$kAG Wagner$$lNeuropsychology$$x15
000272342 980__ $$ajournal
000272342 980__ $$aVDB
000272342 980__ $$aUNRESTRICTED
000272342 980__ $$aI:(DE-2719)5000000
000272342 980__ $$aI:(DE-2719)5000007
000272342 980__ $$aI:(DE-2719)1811005
000272342 980__ $$aI:(DE-2719)1011305
000272342 980__ $$aI:(DE-2719)1011101
000272342 980__ $$aI:(DE-2719)1410006
000272342 980__ $$aI:(DE-2719)1011102
000272342 980__ $$aI:(DE-2719)5000006
000272342 980__ $$aI:(DE-2719)1111015
000272342 980__ $$aI:(DE-2719)5000022
000272342 980__ $$aI:(DE-2719)1510100
000272342 980__ $$aI:(DE-2719)1210000
000272342 980__ $$aI:(DE-2719)1011103
000272342 980__ $$aI:(DE-2719)1011401
000272342 980__ $$aI:(DE-2719)1011303
000272342 980__ $$aI:(DE-2719)1011201
000272342 9801_ $$aFullTexts